Organic Chemical
Belapectin Shows Promising Reduction in Esophageal Varices in MASH Cirrhosis Patients, Despite Missing Primary Endpoint
Belapectin, MASH Cirrhosis, Portal Hypertension, Esophageal Varices, Clinical Trial, Galectin Therapeutics
Applied Therapeutics Undergoes Leadership Changes Amid FDA Rejection and Regulatory Challenges
Applied Therapeutics, leadership changes, FDA rejection, rare disease drug, govorestat, regulatory challenges
CagriSema Achieves 22.7% Weight Loss in Phase 3 REDEFINE 1 Trial, Falling Short of 25% Target
CagriSema, Weight Loss, Phase 3 REDEFINE 1 Trial, Obesity Treatment, Novo Nordisk, Semaglutide, Cagrilintide
Rhythm Pharmaceuticals Secures Expanded FDA Approval for IMCIVREE to Treat Genetic Obesity in Children as Young as 2 Years Old
Rhythm Pharmaceuticals, IMCIVREE, setmelanotide, FDA approval, genetic obesity, Bardet-Biedl syndrome, POMC, PCSK1, LEPR deficiency, pediatric obesity treatment
FDA Issues Complete Response Letter for Zealand Pharma’s Glepaglutide in Short Bowel Syndrome Treatment
Zealand Pharma, Glepaglutide, GLP-2 analog, Short Bowel Syndrome (SBS), FDA rejection, Complete Response Letter
Idorsia’s Restructuring Efforts Continue: Layoffs On Track Despite Delayed Sale of Hypertension Drug Tryvio
Idorsia, Restructuring, Layoffs, Tryvio, Hypertension drug, Aprocitentan, Cost-saving measures, Financial sustainability
Novartis and BioAge Collaborate on Longevity and Exercise Targets for Age-Related Diseases
Novartis, BioAge Labs, Longevity, Exercise Biology, Age-Related Diseases, Therapeutic Targets, Human Longevity Data, Research Collaboration
FDA Approves Ensartinib for First-Line Treatment of ALK-Positive NSCLC
Ensartinib, ALK-positive NSCLC, FDA approval, lung cancer treatment, Xcovery Holdings
Novartis to Consolidate MorphoSys Acquisition with Site Closures and Layoffs
Novartis, MorphoSys, acquisition, consolidation, layoffs, site closures
UCB and Novartis Discontinue Development of Parkinson’s Disease Drug After Phase 2 Failure
UCB, Novartis, Parkinson’s disease, drug development, Phase 2 failure, UCB0599, UCB7853